AIMT - Aimmune Therapeutics, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Show:
Income Statement
Balance Sheet
Cash Flow
Annual

Income Statement

All numbers in thousands
Breakdown
ttm
12/30/2018
12/30/2017
12/30/2016
12/30/2015
Total Revenue
0
0
0
0
0
Cost of Revenue
-
-
-
-
0
Gross Profit
-
-
-
-
0
Operating Expenses
Research Development
128,024
133,420
89,325
54,642
19,816
Selling General and Administrative
101,601
81,921
43,949
26,885
16,181
Total Operating Expenses
229,625
215,341
133,274
81,527
35,997
Operating Income or Loss
-229,625
-215,341
-133,274
-81,527
-35,997
Interest Expense
-
-
-
-
36
Total Other Income/Expenses Net
-
-
-
0
0
Income Before Tax
-225,756
-210,691
-131,269
-80,824
-35,816
Income Tax Expense
88
61
56
0
0
Income from Continuing Operations
-225,844
-210,752
-131,325
-80,824
-35,816
Net Income
-225,844
-210,752
-131,325
-80,824
-35,816
Net Income available to common shareholders
-225,844
-210,752
-131,325
-80,824
-35,816
Reported EPS
Basic
-
-3.67
-2.61
-1.89
-1.88
Diluted
-
-3.67
-2.61
-1.89
-1.88
Weighted average shares outstanding
Basic
-
57,403
50,401
42,751
19,041
Diluted
-
57,403
50,401
42,751
19,041
EBITDA
-
-215,341
-132,308
-81,527
-35,997